Literature DB >> 29159818

C/EBPα-dependent preneoplastic tumor foci are the origin of hepatocellular carcinoma and aggressive pediatric liver cancer.

Ashley Cast1, Leila Valanejad1, Mary Wright1, Phuong Nguyen1, Anita Gupta2, Liqin Zhu3, Soona Shin1, Nikolai Timchenko1.   

Abstract

Recent publications show that classic hepatoblastoma (HBL) is the result of failure of hepatic stem cells to differentiate into hepatocytes, while hepatocellular carcinoma (HCC) is caused by the dedifferentiation of hepatocytes into cancer stem cells. However, the mechanisms of aggressive HBL and the mechanisms that cause dedifferentiation of hepatocytes into cancer stem cells are unknown. We found that, similar to HCC but opposite to classic HBL, aggressive HBL is the result of dedifferentiation of hepatocytes into cancer stem cells. In both cases of liver cancer, the dephosphorylation of tumor suppressor protein CCAAT/enhancer binding protein α (C/EBPα) at Ser193 (Ser190 in human protein) or mutation of Ser193 to Ala results in a modified protein with oncogenic activities. We have investigated liver cancer in a mouse model C/EBPα-S193A, in a large cohort of human HBL samples, and in Pten/p53 double knockout mice and found that these cancers are characterized by elevation of C/EBPα that is dephosphorylated at Ser190/193. We found that dephosphorylated C/EBPα creates preneoplastic foci with cancer stem cells that give rise to HCC and aggressive HBL. C/EBPα-dependent dedifferentiation of hepatocytes into cancer stem cells includes increased proliferation of hepatocytes, followed by generation of multinucleated hepatocytes and subsequent appearance of hepatocytes with delta-like 1 homolog-positive intranuclear inclusions. We further isolated C/EBPα-dependent multinucleated hepatocytes and found that they possess characteristics of tumor-initiating cells, including elevation of stem cell markers. C/EBPα-dependent cancer stem cells are observed in patients with aggressive HBL and in patients with a predisposition for liver cancer.
CONCLUSION: The earliest steps of adult HCC and aggressive pediatric liver cancer have identical features that include conversion of the tumor suppressor C/EBPα into an oncogenic isoform, which further creates preneoplastic foci where hepatocytes dedifferentiate into cancer cells, giving rise to liver cancer. (Hepatology 2018;67:1857-1871).
© 2017 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29159818     DOI: 10.1002/hep.29677

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  22 in total

Review 1.  Cancer stem cells: a major culprit of intra-tumor heterogeneity.

Authors:  Faiza Naz; Mengran Shi; Salvia Sajid; Zhao Yang; Changyuan Yu
Journal:  Am J Cancer Res       Date:  2021-12-15       Impact factor: 6.166

2.  Second Generation Small Molecule Inhibitors of Gankyrin for the Treatment of Pediatric Liver Cancer.

Authors:  Amber M D'Souza; Manu Gnanamony; Maria Thomas; Peter Hanley; Dipti Kanabar; Pedro de Alarcon; Aaron Muth; Nikolai Timchenko
Journal:  Cancers (Basel)       Date:  2022-06-22       Impact factor: 6.575

3.  Molecular Mechanisms of Hepatoblastoma.

Authors:  Yi Zhang; Antonio Solinas; Stefano Cairo; Matthias Evert; Xin Chen; Diego F Calvisi
Journal:  Semin Liver Dis       Date:  2021-01-20       Impact factor: 6.115

4.  The differential expression of perilipin-2 in hepatoblastoma and its association with prognosis.

Authors:  Sadafumi Azukisawa; Jianbo Zheng; Xin Guo; Hiroki Ura; Yo Niida; Tohru Itoh; Sohsuke Yamada
Journal:  Histol Histopathol       Date:  2021-09-03       Impact factor: 2.303

Review 5.  The "Janus" Role of C/EBPs Family Members in Cancer Progression.

Authors:  Manlio Tolomeo; Stefania Grimaudo
Journal:  Int J Mol Sci       Date:  2020-06-17       Impact factor: 5.923

6.  PARP1 activation increases expression of modified tumor suppressors and pathways underlying development of aggressive hepatoblastoma.

Authors:  Leila Valanejad; Ashley Cast; Mary Wright; Karl-Dimiter Bissig; Rebekah Karns; Matthew T Weirauch; Nikolai Timchenko
Journal:  Commun Biol       Date:  2018-06-11

7.  MicroRNA-140-3p enhances the sensitivity of hepatocellular carcinoma cells to sorafenib by targeting pregnenolone X receptor.

Authors:  Jiaqi Li; Jing Zhao; Huan Wang; Xiaohan Li; Aixia Liu; Qin Qin; Boan Li
Journal:  Onco Targets Ther       Date:  2018-09-17       Impact factor: 4.147

8.  Arctigenin Inhibits Liver Cancer Tumorigenesis by Inhibiting Gankyrin Expression via C/EBPα and PPARα.

Authors:  Ying Sun; Yu-Jun Tan; Zhan-Zhao Lu; Bing-Bing Li; Cheng-Hong Sun; Tao Li; Li-Li Zhao; Zhong Liu; Gui-Min Zhang; Jing-Chun Yao; Jie Li
Journal:  Front Pharmacol       Date:  2018-03-27       Impact factor: 5.810

9.  Liver Proliferation Is an Essential Driver of Fibrosis in Mouse Models of Nonalcoholic Fatty Liver Disease.

Authors:  Ashley Cast; Meenasri Kumbaji; Amber D'Souza; Katherine Rodriguez; Anita Gupta; Rebekah Karns; Lubov Timchenko; Nikolai Timchenko
Journal:  Hepatol Commun       Date:  2019-07-17

Review 10.  The Emerging Roles of Cancer Stem Cells and Wnt/Beta-Catenin Signaling in Hepatoblastoma.

Authors:  Nirmala Mavila; Jyothi Thundimadathil
Journal:  Cancers (Basel)       Date:  2019-09-20       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.